A new study looking at PD-L1 expression lung cancer tissue has found that the SP142 assay shows significantly lower levels of PD-L1 expression compared with other available tests.
A new study found that the PD-L1 assay SP142 shows significantly lower levels of PD-L1 expression compared with other available tests. Researchers examined the effectiveness of four assays, finding that the other three-28-8, 22c3, and E1L3N-all showed similar results of PD-L1 expression.
Currently only the 22c3 assay, manufactured by Dako, is required by the US Food and Drug Administration as a companion diagnostic test before treatment with pembrolizumab (Keytruda), an anti–PD-1 immunotherapy approved for the treatment of lung cancer and others.
In this video Robert J. Homer, MD, PhD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, discusses the results.
The study was sponsored by the National Comprehensive Cancer Network (NCCN) and Bristol Myers Squibb.